Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
The ruling brings closure to a nearly decade-long investigation into hospital operations and healthcare delivery practices
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
This collaboration across the NIPER network- Raebareli, Hajipur, Ahmedabad and Hyderabad is strengthening translational research and opnMe access
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Combined platform with 55+ centres aims to expand integrated maternity, fertility, neonatal and paediatric care across India
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations
The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
Subscribe To Our Newsletter & Stay Updated
